Page
|
|
2 - 3
|
|
4 - 5
|
|
6
|
|
7 - 8
|
|
9 - 25
|
March 31, 2025
|
December 31, 2024
|
||||||||||
Note
|
(Unaudited)
|
||||||||||
ASSETS
|
|||||||||||
CURRENT ASSETS:
|
|||||||||||
Cash
|
$
|
1,389
|
$
|
863
|
|||||||
Restricted cash deposit
|
64
|
64
|
|||||||||
Trade receivables
|
16,653
|
13,803
|
|||||||||
Other current assets
|
5,981
|
5,419
|
|||||||||
Inventory
|
3
|
5,433
|
3,215
|
||||||||
29,520
|
23,364
|
||||||||||
NON-CURRENT ASSETS:
|
|||||||||||
Investments in affiliate
|
1,598
|
1,631
|
|||||||||
Property, plant and equipment, net
|
3,752
|
3,730
|
|||||||||
Intangible assets, net
|
3,012
|
3,333
|
|||||||||
Goodwill
|
6,540
|
6,679
|
|||||||||
Right-of-use assets, net
|
512
|
451
|
|||||||||
15,414
|
15,824
|
||||||||||
Total assets
|
$
|
44,934
|
$
|
39,188
|
March 31, 2025
|
December 31, 2024
|
||||||||||
Note
|
(Unaudited)
|
||||||||||
LIABILITIES AND SHAREHOLDERS' EQUITY
|
|||||||||||
CURRENT LIABILITIES:
|
|||||||||||
Current maturities of operating lease liabilities
|
$
|
306
|
$
|
262
|
|||||||
Trade payables
|
16,036
|
11,159
|
|||||||||
Other current liabilities
|
8,677
|
5,001
|
|||||||||
Credit from bank institutions and others
|
12,916
|
15,145
|
|||||||||
Convertible debentures
|
2,042
|
1,968
|
|||||||||
Derivative warrants liabilities and prefunded warrants
|
4
|
817
|
1,383
|
||||||||
40,794
|
34,918
|
||||||||||
NON-CURRENT LIABILITIES:
|
|||||||||||
Operating lease liabilities
|
200
|
171
|
|||||||||
Credit from bank institutions and others
|
314
|
466
|
|||||||||
Deferred tax liabilities
|
453
|
487
|
|||||||||
967
|
1,124
|
||||||||||
Total liabilities
|
41,761
|
36,042
|
|||||||||
EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:
|
5
|
||||||||||
Share capital and premium
|
265,000
|
265,000
|
|||||||||
Capital reserve from translation differences of foreign operations
|
(1,502
|
)
|
(1,265
|
)
|
|||||||
Conversion feature related to convertible debentures
|
297
|
297
|
|||||||||
Capital reserve from share-based payment transactions
|
158
|
150
|
|||||||||
Accumulated deficit
|
(258,629
|
)
|
(258,939
|
)
|
|||||||
Total equity attributable to equity holders of the Company
|
5,324
|
5,243
|
|||||||||
Non-controlling interests
|
(2,151
|
)
|
(2,097
|
)
|
|||||||
Total equity
|
3,173
|
3,146
|
|||||||||
Total liabilities and equity
|
$
|
44,934
|
$ |
39,188
|
Three months ended
March 31,
|
|||||||||||
Note
|
2025
|
2024
|
|||||||||
Revenues
|
$
|
12,500
|
$
|
12,063
|
|||||||
Cost of revenues
|
9,052
|
10,274
|
|||||||||
Gross profit before fair value adjustments
|
3,448
|
1,789
|
|||||||||
Fair value adjustments:
|
|||||||||||
Realized fair value adjustments on inventory sold in the period
|
-
|
(10
|
)
|
||||||||
Total fair value adjustments
|
-
|
(10
|
)
|
||||||||
Gross profit
|
3,448
|
1,779
|
|||||||||
General and administrative expenses
|
2,009
|
2,332
|
|||||||||
Selling and marketing expenses
|
1,273
|
2,292
|
|||||||||
Share-based compensation
|
8
|
32
|
|||||||||
Other operating expenses
|
9
|
-
|
2,753
|
||||||||
Total operating expenses
|
3,290
|
7,409
|
|||||||||
Operating income (loss)
|
158
|
(5,630
|
)
|
||||||||
Finance expense, net
|
4
|
(12
|
)
|
(501
|
)
|
||||||
income (loss) before income taxes
|
146
|
(6,131
|
)
|
||||||||
Income tax benefit
|
29
|
111
|
|||||||||
Net income (loss)
|
$
|
175
|
$
|
(6,020
|
)
|
Three months ended
March 31,
|
|||||||||||
Note
|
2025
|
2024 (
|
*)
|
||||||||
Other comprehensive income that will not be reclassified to profit or loss in subsequent periods:
|
|||||||||||
Total other comprehensive income that will not be reclassified to profit or loss in subsequent periods
|
35
|
67
|
|||||||||
Exchange differences on translation to presentation currency
|
-
|
1,330
|
|||||||||
Total other comprehensive income (loss) that will not be reclassified to profit or loss in subsequent periods
|
35
|
1,397
|
|||||||||
Other comprehensive income that will be reclassified to profit or loss in subsequent periods:
|
|||||||||||
Adjustments arising from translating financial statements of foreign operation
|
(191
|
)
|
(35
|
)
|
|||||||
Total other comprehensive income (loss) that will be reclassified to profit or loss in subsequent periods
|
(191
|
)
|
(35
|
)
|
|||||||
Total other comprehensive income (loss)
|
(156
|
)
|
1,362
|
||||||||
Total comprehensive income (loss)
|
$
|
19
|
$
|
(4,658
|
)
|
||||||
Net income (loss) attributable to:
|
|||||||||||
Equity holders of the Company
|
275
|
(5,623
|
)
|
||||||||
Non-controlling interests
|
(100
|
)
|
(397
|
)
|
|||||||
$
|
175
|
$
|
(6,020
|
)
|
|||||||
Total comprehensive income (loss) attributable to:
|
|||||||||||
Equity holders of the Company
|
73
|
(4,252
|
)
|
||||||||
Non-controlling interests
|
(54
|
)
|
(406
|
)
|
|||||||
$
|
19
|
$
|
(4,658
|
)
|
|||||||
Net income (loss) per share attributable to equity holders of the Company:
|
7
|
||||||||||
Basic and diluted income (loss) per share (in CAD)
|
$
|
0.09
|
$
|
(2.52
|
)
|
(*) |
Loss per share includes the effect of Reverse Share Split (see also Note 5a below).
|
Share capital and premium
|
Reserve from share-based payment transactions
|
Conversion option for convertible debt
|
Translation reserve
|
Accumulated deficit
|
Total
|
Non-controlling interests
|
Total
equity
|
|||||||||||||||||||||||||
Balance as of January 1, 2025
|
$
|
265,000
|
$
|
150
|
$
|
297
|
$
|
(1,265
|
)
|
$
|
(258,939
|
)
|
$
|
5,243
|
$
|
(2,097
|
)
|
$
|
3,146
|
|||||||||||||
Net income (Loss)
|
-
|
-
|
-
|
-
|
275
|
275
|
(100
|
)
|
175
|
|||||||||||||||||||||||
Total other comprehensive income (loss)
|
-
|
-
|
-
|
(237
|
)
|
35
|
(202
|
)
|
46
|
(156
|
)
|
|||||||||||||||||||||
Total comprehensive loss
|
-
|
-
|
-
|
(237
|
)
|
310
|
73
|
(54
|
)
|
19
|
||||||||||||||||||||||
Share-based compensation
|
-
|
8
|
-
|
-
|
8
|
-
|
8
|
|||||||||||||||||||||||||
Balance as of March 31, 2025
|
$
|
265,000
|
$
|
158
|
$
|
297
|
$
|
(1,502
|
)
|
$
|
(258,629
|
)
|
$
|
5,324
|
$
|
(2,151
|
)
|
$
|
3,173
|
Share
Capital and premium
|
Reserve from share-based payment transactions
|
Translation reserve
|
Accumulated deficit
|
Total
|
Non-controlling interests
|
Total
equity
|
||||||||||||||||||||||
Balance as of January 1, 2024
|
$
|
253,882
|
$
|
9,637
|
$
|
95
|
$
|
(249,145
|
)
|
$
|
14,469
|
$
|
(769
|
)
|
$
|
13,700
|
||||||||||||
Net loss
|
-
|
-
|
-
|
(5,623
|
)
|
(5,623
|
)
|
(397
|
)
|
(6,020
|
)
|
|||||||||||||||||
Total other comprehensive loss
|
-
|
-
|
1,304
|
67
|
1,371
|
(9
|
)
|
1,362
|
||||||||||||||||||||
Total comprehensive loss
|
-
|
-
|
1,304
|
(5,556
|
)
|
(4,252
|
)
|
(406
|
)
|
(4,658
|
)
|
|||||||||||||||||
Other comprehensive income Classification
|
-
|
-
|
-
|
(730
|
)
|
(730
|
)
|
-
|
(730
|
)
|
||||||||||||||||||
Share-based compensation
|
-
|
32
|
-
|
-
|
32
|
-
|
32
|
|||||||||||||||||||||
Forfeited options
|
5
|
(5
|
)
|
-
|
-
|
-
|
-
|
-
|
||||||||||||||||||||
Balance as of March 31, 2024
|
$
|
253,887
|
$
|
9,664
|
$
|
1,399
|
$
|
(255,431
|
)
|
$
|
9,519
|
$
|
(1,175
|
)
|
$
|
8,344
|
Three months ended
March 31,
|
||||||||
2025
|
2024
|
|||||||
Cash provided by operating activities:
|
||||||||
Net income (loss)
|
$
|
175
|
$
|
(6,020
|
)
|
|||
Adjustments for non-cash items:
|
||||||||
Fair value adjustment on sale of inventory
|
-
|
10
|
||||||
Fair value adjustment on Warrants, investments and accounts receivable
|
(565
|
)
|
100
|
|||||
Interest recorded in respect of the convertible debt
|
73
|
-
|
||||||
Depreciation of property, plant and equipment
|
46
|
147
|
||||||
Amortization of intangible assets
|
338
|
452
|
||||||
Depreciation of right-of-use assets
|
79
|
118
|
||||||
Impairment of PPE
|
-
|
2,753
|
||||||
Finance expenses, net
|
504
|
401
|
||||||
Deferred tax liability, net
|
(40
|
)
|
(69
|
)
|
||||
Share-based payment
|
8
|
32
|
||||||
Discount expenses in respect of credit
|
36
|
-
|
||||||
479
|
3,944
|
|||||||
Changes in working capital:
|
||||||||
Increase (decrease) in trade receivables
|
(3,245
|
)
|
1,332
|
|||||
Increase (decrease) in other accounts receivable and advances to suppliers
|
(1,405
|
)
|
159
|
|||||
Increase (decrease) in inventories, net of fair value adjustments
|
(2,349
|
)
|
2,159
|
|||||
Increase in trade payables
|
5,270
|
663
|
||||||
Increase (decrease) in other accounts payable and accrued expenses
|
5,544
|
(2,745
|
)
|
|||||
3,815
|
1,568
|
|||||||
Taxes paid
|
(6
|
)
|
(121
|
)
|
||||
Net cash provided (used) in operating activities
|
4,463
|
(629
|
)
|
|||||
Cash flows from investing activities:
|
||||||||
Purchase of property, plant and equipment
|
-
|
(2
|
)
|
|||||
Net cash used in investing activities
|
$
|
-
|
$
|
(2
|
)
|
Three months ended
March 31,
|
||||||||
2025
|
2024
|
|||||||
Cash flow from financing activities:
|
||||||||
Proceeds from issuance of share capital, net of issuance costs
|
-
|
176
|
||||||
Proceeds from issuance of warrants
|
-
|
(176
|
)
|
|||||
Repayment of lease liability
|
(68
|
)
|
(118
|
)
|
||||
Interest paid - lease liability
|
(10
|
)
|
(15
|
)
|
||||
Repayment of bank loan and credit facilities
|
(594
|
)
|
(2,856
|
)
|
||||
Cash paid for interest
|
(976
|
)
|
(444
|
)
|
||||
Proceeds (repayments) from discounted checks
|
(1,224
|
)
|
2,581
|
|||||
Net cash provided (used) by financing activities
|
(2,872
|
)
|
(852
|
)
|
||||
Effect of foreign exchange on cash and cash equivalents
|
(1,065
|
)
|
718
|
|||||
Increase (decrease) in cash and cash equivalents
|
526
|
(765
|
)
|
|||||
Cash and cash equivalents at the beginning of the period
|
863
|
1,813
|
||||||
Cash and cash equivalents at end of the period
|
$
|
1,389
|
$
|
1,048
|
||||
Supplemental disclosure of non-cash activities:
|
||||||||
Right-of-use asset recognized with corresponding lease liability
|
$
|
159
|
$
|
40
|
NOTE 1 - |
GENERAL
|
a.
|
Corporate information
|
NOTE 1 - |
GENERAL (Cont.)
|
NOTE 1 - |
GENERAL (Cont.)
|
NOTE 1 - |
GENERAL (Cont.)
|
NOTE 1 - |
GENERAL (Cont.)
|
NOTE 1 - |
GENERAL (Cont.)
|
NOTE 1 - |
GENERAL (Cont.)
|
b. |
Approval of consolidated financial statements:
|
c. |
Definitions:
|
The Company, or IMCC
|
-
|
IM Cannabis Corp.
|
|
The Group
|
-
|
IM Cannabis Corp., its Subsidiaries
|
|
Subsidiaries
|
-
|
Companies that are controlled by the Company (as defined in IFRS 10) and whose accounts are consolidated with those of the Company
|
|
CAD or $
|
-
|
Canadian Dollar
|
|
NIS
|
-
|
New Israeli Shekel
|
NOTE 2 -
|
SIGNIFICANT ACCOUNTING POLICIES
|
a. |
Basis of Presentation and Measurement:
|
a. |
Amendments to IAS 21, Lack of Exchangeability:
|
b. |
Significant Accounting Judgements and Estimates:
|
NOTE 3:-
|
INVENTORIES
|
March 31, 2025
|
December 31, 2024
|
|||||||
Work in progress:
|
||||||||
Bulk cannabis
|
$
|
521
|
$
|
325
|
||||
Finished goods
|
||||||||
Packaged dried cannabis
|
4,832
|
2,605
|
||||||
Other products
|
80
|
285
|
||||||
Balance as of March 31, 2025
|
$
|
5,433
|
$
|
3,215
|
NOTE 4:-
|
FINANCIAL INSTRUMENTS
|
A. |
Financial instruments are measured either at fair value or at amortized cost. The table below lists the valuation methods used to determine fair value of each financial instrument.
|
Financial Instruments Measured at Fair Value
|
Fair Value Method
|
|
Liability for Warrants *)
Investment in Xinteza
|
Black & Scholes model (Level 3 category)
Market comparable (Level 3 category)
|
*) |
Finance (income) expense from revaluation of Warrants measured at fair value, for the three months ended March 31, 2025 and 2024, amounted to $(565) and $100, respectively.
|
Issue date
|
|||||||||
Series 2024
|
Series 2023
|
Series 2021
|
|||||||
Expected volatility
|
77.69%
|
|
74.31%
|
|
74.3%
|
|
|||
Share price (Canadian Dollar)
|
2.46
|
2.17
|
2.17
|
||||||
Expected life (in years)
|
1.636
|
1.110
|
1.110
|
||||||
Risk-free interest rate
|
4.13%
|
|
4.23%
|
|
4.23%
|
|
|||
Expected dividend yield
|
0%
|
|
0%
|
|
0%
|
|
|||
Per Warrant (Canadian Dollar)
|
$0.592
|
$0.017
|
$0
|
||||||
Total Warrants (Canadian Dollar in thousands)
|
$440
|
$1
|
$1
|
B. |
On May 26, 2024, the Company has closed a non-brokered private placement of Debentures of the Company. The Debentures fair value for the issuance date was measured using 16.55% IRR and was summarized to $1,795 of Convertible Debt and
$297 of conversion option for Convertible Debt.
|
NOTE 5:-
|
EQUITY
|
a. |
Composition of share capital:
|
March 31,
|
December 31,
|
|||||||||
2025
|
2024
|
|||||||||
Authorized
|
Issued and outstanding
|
Authorized
|
Issued and outstanding
|
|||||||
Common Shares without par value
|
Unlimited
|
3,085,452
|
Unlimited
|
3,085,452
|
b. |
Capital issuances:
|
NOTE 5:-
|
EQUITY (Cont.)
|
NOTE 5:-
|
EQUITY (Cont.)
|
c. |
Changes in issued and outstanding share capital:
|
Number of shares
|
||||
Balance as of January 1, 2025
|
3,085,452
|
|||
Issuance of Common Shares
|
-
|
|||
Balance as of March 31, 2025
|
3,085,452
|
Three months ended March 31, 2025
|
||||||||
Number of options
|
Weighted average exercise price
|
|||||||
in CAD
|
||||||||
Options outstanding at the beginning of the period
|
34,576
|
$
|
4.71
|
|||||
Options forfeited during the period
|
-
|
-
|
||||||
Options outstanding at the end of the period
|
34,576
|
$
|
4.71
|
|||||
Options exercisable at the end of the period
|
11,474
|
$
|
16.32
|
NOTE 6:- |
SELECTED STATEMENTS OF PROFIT OR LOSS DATA
|
Three months ended
March 31,
|
||||||||
2025
|
2024
|
|||||||
Salaries and related expenses
|
$
|
1,346
|
$
|
1,878
|
||||
Depreciation and amortization
|
$
|
463
|
$
|
680
|
NOTE 7:-
|
NET EARNINGS (LOSS) PER SHARE
|
Three months ended March 31,
|
||||||||||||||||
2025
|
2024
|
|||||||||||||||
Weighted average number of shares (in thousands)
|
Net income attributable to equity holders of the Company
|
Weighted average number of shares (in thousands)
(*)
|
Net loss attributable to equity holders of the Company
|
|||||||||||||
For the computation of basic net earnings
|
3,085
|
$
|
275
|
2,232
|
$
|
(5,623
|
)
|
|||||||||
Effect of potential dilutive Common Shares
|
-
|
-
|
-
|
-
|
||||||||||||
For the computation of diluted net earnings
|
3,085
|
$
|
275
|
2,232
|
$
|
(5,623
|
)
|
NOTE 8:- |
OPERATING SEGMENTS
|
a. |
Reporting operating segments:
|
Israel
|
Germany
|
Adjustments
|
Total
|
|||||||||||||
Revenue
|
$
|
4,795
|
$
|
7,705
|
$
|
-
|
$
|
12,500
|
||||||||
Segment gain (loss)
|
$
|
111
|
$
|
577
|
$
|
-
|
$
|
688
|
||||||||
Unallocated corporate expenses
|
$
|
(530
|
)
|
$
|
(530
|
)
|
||||||||||
Total operating income
|
$
|
158
|
||||||||||||||
Depreciation, amortization and impairment
|
$
|
439
|
$
|
24
|
$
|
-
|
$
|
463
|
Israel
|
Germany
|
Adjustments
|
Total
|
|||||||||||||
Revenue
|
$
|
10,911
|
$
|
1,152
|
$
|
-
|
$
|
12,063
|
||||||||
Segment loss
|
$
|
(4,508
|
)
|
$
|
(316
|
)
|
$
|
-
|
$
|
(4,824
|
)
|
|||||
Unallocated corporate expenses
|
$
|
(806
|
)
|
$
|
(806
|
)
|
||||||||||
Total operating loss
|
$
|
(5,630
|
)
|
|||||||||||||
Depreciation, amortization and impairment
|
$
|
655
|
$
|
25
|
$
|
-
|
$
|
680
|
NOTE 9:- |
DECONSOLIDATION OF ORANIM PHARMACY
|
April 15,
2024
|
December 31,
2023
|
|||||||
ASSETS
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
346
|
$
|
308
|
||||
Trade receivables
|
1,324
|
1,289
|
||||||
Other accounts receivable
|
759
|
761
|
||||||
Inventories
|
837
|
725
|
||||||
3,266
|
3,083
|
|||||||
Non-current assets:
|
||||||||
Property, plant and equipment, net
|
783
|
802
|
||||||
Right-of-use assets, net
|
533
|
565
|
||||||
Intangible assets, net
|
1,414
|
1,575
|
||||||
Goodwill
|
3,499
|
3,455
|
||||||
6,229
|
6,397
|
|||||||
Total Assets
|
$
|
9,495
|
$
|
9,480
|
April 15,
2024
|
December 31,
2023
|
|||||||
LIABILITIES
|
||||||||
Current liabilities:
|
||||||||
Trade payables
|
$
|
1,597
|
$
|
1,477
|
||||
Other accounts payable and accrued expenses
|
166
|
230
|
||||||
Current maturities of operating lease liabilities
|
155
|
152
|
||||||
1,918
|
1,859
|
|||||||
Non-current liabilities:
|
||||||||
Lease liabilities
|
372
|
406
|
||||||
Deferred tax liability, net
|
326
|
364
|
||||||
698
|
770
|
|||||||
Total liabilities
|
$
|
2,616
|
$
|
2,629
|
||||
Purchase consideration payable
|
$
|
2,172
|
$
|
2,097
|
||||
Put option liability
|
$
|
1,973
|
$
|
2,697
|
NOTE 10:- |
SUBSEQUENT EVENTS
|
a. |
On April 29, 2025, IMC Holdings entered into a short-term loan agreement, with a non-financial institute in the amount of NIS 1,000 thousand (approximately $387). This loan bears interest at an annual rate of 17% and mature 12 months
from the date of signing the loan agreement.
|
b. |
On April 29, 2025, the Company's chairman of the Board and the Chief Executive Officer, loaned an amount of NIS 1,000 (approximately $387) to IMC Holdings. The loan shall bear fixed annual interest at the rate prescribed by the Income
Tax Regulations for determining the interest rate under Section 3(i) of the Income Tax Ordinance.
|
c. |
On April 9, 2025, the Company received a written notification (the "Notification Letter") from the Nasdaq Stock Market, notifying the Company that it is no longer in compliance with Nasdaq Stock Market Listing Rule 5550(b)(1). Nasdaq
Stock Market Listing Rule 5550(b)(1) (the "Listing Rule") requires companies listed on the Nasdaq Capital Market to maintain a minimum of US$2.5 million in stockholders' equity for continued listing.
|